BI 655064

Drug Profile

BI 655064

Alternative Names: BI-655064

Latest Information Update: 13 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Boehringer Ingelheim
  • Class Antirheumatics; Monoclonal antibodies
  • Mechanism of Action CD40 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Lupus nephritis
  • Phase I Idiopathic thrombocytopenic purpura; Rheumatoid arthritis

Most Recent Events

  • 15 Dec 2017 Boehringer Ingelheim initiates a long term extension trial for Lupus nephritis in Greece (EudraCT2017-003101-17)
  • 14 Jun 2017 Preclinical pharmacodynamics data in Proteinuria and Nephritis presented at the 18th Annual Congress of the European League Against Rheumatism (EULAR-2017)
  • 11 Nov 2016 Efficacy, adverse events, pharmacodynamics and immunogenecity data from a phase I trial in Rheumatoid arthritis presented at the 80th American College of Rheumatology and the 51st Annual Meeting of the Association of Rheumatology and Health Professionals (ACR-ARHP-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top